Cargando…

A Vimentin-Targeting Oral Compound with Host-Directed Antiviral and Anti-Inflammatory Actions Addresses Multiple Features of COVID-19 and Related Diseases

Damage in COVID-19 results from both the SARS-CoV-2 virus and its triggered overactive host immune responses. Therapeutic agents that focus solely on reducing viral load or hyperinflammation fail to provide satisfying outcomes in all cases. Although viral and cellular factors have been extensively p...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zhizhen, Wu, Jianping, Zhou, Ji, Yuan, Baoshi, Chen, Jiqiao, Wu, Wanchen, Mo, Lian, Qu, Zhipeng, Zhou, Fei, Dong, Yingying, Huang, Kai, Liu, Zhiwei, Wang, Tao, Symmes, Deebie, Gu, Jingliang, Sho, Eiketsu, Zhang, Jingping, Chen, Ruihuan, Xu, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510534/
https://www.ncbi.nlm.nih.gov/pubmed/34634931
http://dx.doi.org/10.1128/mBio.02542-21
_version_ 1784582595039723520
author Li, Zhizhen
Wu, Jianping
Zhou, Ji
Yuan, Baoshi
Chen, Jiqiao
Wu, Wanchen
Mo, Lian
Qu, Zhipeng
Zhou, Fei
Dong, Yingying
Huang, Kai
Liu, Zhiwei
Wang, Tao
Symmes, Deebie
Gu, Jingliang
Sho, Eiketsu
Zhang, Jingping
Chen, Ruihuan
Xu, Ying
author_facet Li, Zhizhen
Wu, Jianping
Zhou, Ji
Yuan, Baoshi
Chen, Jiqiao
Wu, Wanchen
Mo, Lian
Qu, Zhipeng
Zhou, Fei
Dong, Yingying
Huang, Kai
Liu, Zhiwei
Wang, Tao
Symmes, Deebie
Gu, Jingliang
Sho, Eiketsu
Zhang, Jingping
Chen, Ruihuan
Xu, Ying
author_sort Li, Zhizhen
collection PubMed
description Damage in COVID-19 results from both the SARS-CoV-2 virus and its triggered overactive host immune responses. Therapeutic agents that focus solely on reducing viral load or hyperinflammation fail to provide satisfying outcomes in all cases. Although viral and cellular factors have been extensively profiled to identify potential anti-COVID-19 targets, new drugs with significant efficacy remain to be developed. Here, we report the potent preclinical efficacy of ALD-R491, a vimentin-targeting small molecule compound, in treating COVID-19 through its host-directed antiviral and anti-inflammatory actions. We found that by altering the physical properties of vimentin filaments, ALD-491 affected general cellular processes as well as specific cellular functions relevant to SARS-CoV-2 infection. Specifically, ALD-R491 reduced endocytosis, endosomal trafficking, and exosomal release, thus impeding the entry and egress of the virus; increased the microcidal capacity of macrophages, thus facilitating the pathogen clearance; and enhanced the activity of regulatory T cells, therefore suppressing the overactive immune responses. In cultured cells, ALD-R491 potently inhibited the SARS-CoV-2 spike protein and human ACE2-mediated pseudoviral infection. In aged mice with ongoing, productive SARS-CoV-2 infection, ALD-R491 reduced disease symptoms as well as lung damage. In rats, ALD-R491 also reduced bleomycin-induced lung injury and fibrosis. Our results indicate a unique mechanism and significant therapeutic potential for ALD-R491 against COVID-19. We anticipate that ALD-R491, an oral, fast-acting, and non-cytotoxic agent targeting the cellular protein with multipart actions, will be convenient, safe, and broadly effective, regardless of viral mutations, for patients with early- or late-stage disease, post-COVID-19 complications, and other related diseases.
format Online
Article
Text
id pubmed-8510534
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-85105342021-10-20 A Vimentin-Targeting Oral Compound with Host-Directed Antiviral and Anti-Inflammatory Actions Addresses Multiple Features of COVID-19 and Related Diseases Li, Zhizhen Wu, Jianping Zhou, Ji Yuan, Baoshi Chen, Jiqiao Wu, Wanchen Mo, Lian Qu, Zhipeng Zhou, Fei Dong, Yingying Huang, Kai Liu, Zhiwei Wang, Tao Symmes, Deebie Gu, Jingliang Sho, Eiketsu Zhang, Jingping Chen, Ruihuan Xu, Ying mBio Research Article Damage in COVID-19 results from both the SARS-CoV-2 virus and its triggered overactive host immune responses. Therapeutic agents that focus solely on reducing viral load or hyperinflammation fail to provide satisfying outcomes in all cases. Although viral and cellular factors have been extensively profiled to identify potential anti-COVID-19 targets, new drugs with significant efficacy remain to be developed. Here, we report the potent preclinical efficacy of ALD-R491, a vimentin-targeting small molecule compound, in treating COVID-19 through its host-directed antiviral and anti-inflammatory actions. We found that by altering the physical properties of vimentin filaments, ALD-491 affected general cellular processes as well as specific cellular functions relevant to SARS-CoV-2 infection. Specifically, ALD-R491 reduced endocytosis, endosomal trafficking, and exosomal release, thus impeding the entry and egress of the virus; increased the microcidal capacity of macrophages, thus facilitating the pathogen clearance; and enhanced the activity of regulatory T cells, therefore suppressing the overactive immune responses. In cultured cells, ALD-R491 potently inhibited the SARS-CoV-2 spike protein and human ACE2-mediated pseudoviral infection. In aged mice with ongoing, productive SARS-CoV-2 infection, ALD-R491 reduced disease symptoms as well as lung damage. In rats, ALD-R491 also reduced bleomycin-induced lung injury and fibrosis. Our results indicate a unique mechanism and significant therapeutic potential for ALD-R491 against COVID-19. We anticipate that ALD-R491, an oral, fast-acting, and non-cytotoxic agent targeting the cellular protein with multipart actions, will be convenient, safe, and broadly effective, regardless of viral mutations, for patients with early- or late-stage disease, post-COVID-19 complications, and other related diseases. American Society for Microbiology 2021-10-12 /pmc/articles/PMC8510534/ /pubmed/34634931 http://dx.doi.org/10.1128/mBio.02542-21 Text en Copyright © 2021 Li et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Li, Zhizhen
Wu, Jianping
Zhou, Ji
Yuan, Baoshi
Chen, Jiqiao
Wu, Wanchen
Mo, Lian
Qu, Zhipeng
Zhou, Fei
Dong, Yingying
Huang, Kai
Liu, Zhiwei
Wang, Tao
Symmes, Deebie
Gu, Jingliang
Sho, Eiketsu
Zhang, Jingping
Chen, Ruihuan
Xu, Ying
A Vimentin-Targeting Oral Compound with Host-Directed Antiviral and Anti-Inflammatory Actions Addresses Multiple Features of COVID-19 and Related Diseases
title A Vimentin-Targeting Oral Compound with Host-Directed Antiviral and Anti-Inflammatory Actions Addresses Multiple Features of COVID-19 and Related Diseases
title_full A Vimentin-Targeting Oral Compound with Host-Directed Antiviral and Anti-Inflammatory Actions Addresses Multiple Features of COVID-19 and Related Diseases
title_fullStr A Vimentin-Targeting Oral Compound with Host-Directed Antiviral and Anti-Inflammatory Actions Addresses Multiple Features of COVID-19 and Related Diseases
title_full_unstemmed A Vimentin-Targeting Oral Compound with Host-Directed Antiviral and Anti-Inflammatory Actions Addresses Multiple Features of COVID-19 and Related Diseases
title_short A Vimentin-Targeting Oral Compound with Host-Directed Antiviral and Anti-Inflammatory Actions Addresses Multiple Features of COVID-19 and Related Diseases
title_sort vimentin-targeting oral compound with host-directed antiviral and anti-inflammatory actions addresses multiple features of covid-19 and related diseases
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510534/
https://www.ncbi.nlm.nih.gov/pubmed/34634931
http://dx.doi.org/10.1128/mBio.02542-21
work_keys_str_mv AT lizhizhen avimentintargetingoralcompoundwithhostdirectedantiviralandantiinflammatoryactionsaddressesmultiplefeaturesofcovid19andrelateddiseases
AT wujianping avimentintargetingoralcompoundwithhostdirectedantiviralandantiinflammatoryactionsaddressesmultiplefeaturesofcovid19andrelateddiseases
AT zhouji avimentintargetingoralcompoundwithhostdirectedantiviralandantiinflammatoryactionsaddressesmultiplefeaturesofcovid19andrelateddiseases
AT yuanbaoshi avimentintargetingoralcompoundwithhostdirectedantiviralandantiinflammatoryactionsaddressesmultiplefeaturesofcovid19andrelateddiseases
AT chenjiqiao avimentintargetingoralcompoundwithhostdirectedantiviralandantiinflammatoryactionsaddressesmultiplefeaturesofcovid19andrelateddiseases
AT wuwanchen avimentintargetingoralcompoundwithhostdirectedantiviralandantiinflammatoryactionsaddressesmultiplefeaturesofcovid19andrelateddiseases
AT molian avimentintargetingoralcompoundwithhostdirectedantiviralandantiinflammatoryactionsaddressesmultiplefeaturesofcovid19andrelateddiseases
AT quzhipeng avimentintargetingoralcompoundwithhostdirectedantiviralandantiinflammatoryactionsaddressesmultiplefeaturesofcovid19andrelateddiseases
AT zhoufei avimentintargetingoralcompoundwithhostdirectedantiviralandantiinflammatoryactionsaddressesmultiplefeaturesofcovid19andrelateddiseases
AT dongyingying avimentintargetingoralcompoundwithhostdirectedantiviralandantiinflammatoryactionsaddressesmultiplefeaturesofcovid19andrelateddiseases
AT huangkai avimentintargetingoralcompoundwithhostdirectedantiviralandantiinflammatoryactionsaddressesmultiplefeaturesofcovid19andrelateddiseases
AT liuzhiwei avimentintargetingoralcompoundwithhostdirectedantiviralandantiinflammatoryactionsaddressesmultiplefeaturesofcovid19andrelateddiseases
AT wangtao avimentintargetingoralcompoundwithhostdirectedantiviralandantiinflammatoryactionsaddressesmultiplefeaturesofcovid19andrelateddiseases
AT symmesdeebie avimentintargetingoralcompoundwithhostdirectedantiviralandantiinflammatoryactionsaddressesmultiplefeaturesofcovid19andrelateddiseases
AT gujingliang avimentintargetingoralcompoundwithhostdirectedantiviralandantiinflammatoryactionsaddressesmultiplefeaturesofcovid19andrelateddiseases
AT shoeiketsu avimentintargetingoralcompoundwithhostdirectedantiviralandantiinflammatoryactionsaddressesmultiplefeaturesofcovid19andrelateddiseases
AT zhangjingping avimentintargetingoralcompoundwithhostdirectedantiviralandantiinflammatoryactionsaddressesmultiplefeaturesofcovid19andrelateddiseases
AT chenruihuan avimentintargetingoralcompoundwithhostdirectedantiviralandantiinflammatoryactionsaddressesmultiplefeaturesofcovid19andrelateddiseases
AT xuying avimentintargetingoralcompoundwithhostdirectedantiviralandantiinflammatoryactionsaddressesmultiplefeaturesofcovid19andrelateddiseases
AT lizhizhen vimentintargetingoralcompoundwithhostdirectedantiviralandantiinflammatoryactionsaddressesmultiplefeaturesofcovid19andrelateddiseases
AT wujianping vimentintargetingoralcompoundwithhostdirectedantiviralandantiinflammatoryactionsaddressesmultiplefeaturesofcovid19andrelateddiseases
AT zhouji vimentintargetingoralcompoundwithhostdirectedantiviralandantiinflammatoryactionsaddressesmultiplefeaturesofcovid19andrelateddiseases
AT yuanbaoshi vimentintargetingoralcompoundwithhostdirectedantiviralandantiinflammatoryactionsaddressesmultiplefeaturesofcovid19andrelateddiseases
AT chenjiqiao vimentintargetingoralcompoundwithhostdirectedantiviralandantiinflammatoryactionsaddressesmultiplefeaturesofcovid19andrelateddiseases
AT wuwanchen vimentintargetingoralcompoundwithhostdirectedantiviralandantiinflammatoryactionsaddressesmultiplefeaturesofcovid19andrelateddiseases
AT molian vimentintargetingoralcompoundwithhostdirectedantiviralandantiinflammatoryactionsaddressesmultiplefeaturesofcovid19andrelateddiseases
AT quzhipeng vimentintargetingoralcompoundwithhostdirectedantiviralandantiinflammatoryactionsaddressesmultiplefeaturesofcovid19andrelateddiseases
AT zhoufei vimentintargetingoralcompoundwithhostdirectedantiviralandantiinflammatoryactionsaddressesmultiplefeaturesofcovid19andrelateddiseases
AT dongyingying vimentintargetingoralcompoundwithhostdirectedantiviralandantiinflammatoryactionsaddressesmultiplefeaturesofcovid19andrelateddiseases
AT huangkai vimentintargetingoralcompoundwithhostdirectedantiviralandantiinflammatoryactionsaddressesmultiplefeaturesofcovid19andrelateddiseases
AT liuzhiwei vimentintargetingoralcompoundwithhostdirectedantiviralandantiinflammatoryactionsaddressesmultiplefeaturesofcovid19andrelateddiseases
AT wangtao vimentintargetingoralcompoundwithhostdirectedantiviralandantiinflammatoryactionsaddressesmultiplefeaturesofcovid19andrelateddiseases
AT symmesdeebie vimentintargetingoralcompoundwithhostdirectedantiviralandantiinflammatoryactionsaddressesmultiplefeaturesofcovid19andrelateddiseases
AT gujingliang vimentintargetingoralcompoundwithhostdirectedantiviralandantiinflammatoryactionsaddressesmultiplefeaturesofcovid19andrelateddiseases
AT shoeiketsu vimentintargetingoralcompoundwithhostdirectedantiviralandantiinflammatoryactionsaddressesmultiplefeaturesofcovid19andrelateddiseases
AT zhangjingping vimentintargetingoralcompoundwithhostdirectedantiviralandantiinflammatoryactionsaddressesmultiplefeaturesofcovid19andrelateddiseases
AT chenruihuan vimentintargetingoralcompoundwithhostdirectedantiviralandantiinflammatoryactionsaddressesmultiplefeaturesofcovid19andrelateddiseases
AT xuying vimentintargetingoralcompoundwithhostdirectedantiviralandantiinflammatoryactionsaddressesmultiplefeaturesofcovid19andrelateddiseases